Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03016598 · ClinicalTrials.gov registry record · Phase 2
Stimulant Oxytocin Study
A Phase 2 study of Stimulant Use & Co-occuring Opioid Use Disorders, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 3
- Study locations
NCT03016598 is a Phase 2 study of Stimulant Use & Co-occuring Opioid Use Disorders that has completed, run by VA Office of Research and Development. The registered enrollment target is 42 participants. The trial reports 3 study locations across 2 states.
The verdict
NCT03016598, a Phase 2 study of Stimulant Use & Co-occuring Opioid Use Disorders, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will investigate the effects of intranasal administration of oxytocin, a social neuropeptide, on reducing stimulant use, enhancing therapeutic engagement, and susceptibility to stress-induced relapse in Veterans with stimulant use disorders and enrolled in opioid replacement therapy (ORT) program for co-occurring opioid use disorder (OUD).
Conditions Studied
Interventions
- DRUG Intranasal oxytocin
- DRUG Intranasal placebo
Study Locations (3)
California
- VA Northern California Health Care System, Mather, CA - Sacramento
- San Francisco VA Medical Center, San Francisco, CA - San Francisco
Oregon
- VA Portland Health Care System, Portland, OR - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2018-01-26 |
| Est. Completion | 2020-02-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03016598
The ClinicalTrials.gov registry entry for NCT03016598 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stimulant Use & Co-occuring Opioid Use Disorders appearing as the primary indexed condition, and to 2 interventions - of which Intranasal oxytocin is the first listed.
NCT03016598 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Oregon.
Frequently Asked Questions
What is clinical trial NCT03016598 about?
NCT03016598 is a clinical study titled "Stimulant Oxytocin Study". This study will investigate the effects of intranasal administration of oxytocin, a social neuropeptide, on reducing stimulant use, enhancing therapeutic engagement, and susceptibility to stress-induced relapse in Veterans with stimulant use disorders and enrolled in opioid replacement therapy (ORT)...
What is the current status of trial NCT03016598?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2018-01-26. Estimated completion is 2020-02-14.
What conditions does trial NCT03016598 study?
This clinical trial studies the following conditions: Stimulant Use & Co-occuring Opioid Use Disorders.
What interventions are being tested in trial NCT03016598?
The interventions under investigation include: Intranasal oxytocin (DRUG), Intranasal placebo (DRUG).
Who is sponsoring clinical trial NCT03016598?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03016598 being conducted?
This trial has 3 study locations across California, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.